Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3818496rdf:typepubmed:Citationlld:pubmed
pubmed-article:3818496lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:3818496lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:3818496lifeskim:mentionsumls-concept:C0025893lld:lifeskim
pubmed-article:3818496lifeskim:mentionsumls-concept:C0277785lld:lifeskim
pubmed-article:3818496pubmed:issue6lld:pubmed
pubmed-article:3818496pubmed:dateCreated1987-4-1lld:pubmed
pubmed-article:3818496pubmed:abstractTextThe pharmacokinetics of mezlocillin were investigated in 26 patients with alcoholic liver disease. Serum concentrations of mezlocillin were measured following intravenous administration of 3 g doses over 30 min. The mean peak serum concentration (+/- standard deviation) of mezlocillin at the end of infusion was 138.8 +/- 55.7 mg/l and the mean terminal half-life (T 1/2 beta) was 2.10 +/- 0.9 h. The 24 h urinary recovery of mezlocillin was 35.4 +/- 12.4% of the administered dose. Serum clearance was found to be inversely correlated with alkaline phosphatase and with total bilirubin. The T 1/2 beta was related to the following clinical measurements: age, SGOT and prothrombin time. This relationship suggests it may be prudent to adjust the dosage and the dosage interval of mezlocillin in patients with hepatobiliary dysfunction.lld:pubmed
pubmed-article:3818496pubmed:languageenglld:pubmed
pubmed-article:3818496pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3818496pubmed:citationSubsetIMlld:pubmed
pubmed-article:3818496pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3818496pubmed:statusMEDLINElld:pubmed
pubmed-article:3818496pubmed:monthDeclld:pubmed
pubmed-article:3818496pubmed:issn0305-7453lld:pubmed
pubmed-article:3818496pubmed:authorpubmed-author:WornerT MTMlld:pubmed
pubmed-article:3818496pubmed:authorpubmed-author:HirschmanS...lld:pubmed
pubmed-article:3818496pubmed:authorpubmed-author:JacobsonJJlld:pubmed
pubmed-article:3818496pubmed:authorpubmed-author:SacksH SHSlld:pubmed
pubmed-article:3818496pubmed:authorpubmed-author:MeyersB RBRlld:pubmed
pubmed-article:3818496pubmed:authorpubmed-author:WormserG PGPlld:pubmed
pubmed-article:3818496pubmed:authorpubmed-author:SrulevitchE...lld:pubmed
pubmed-article:3818496pubmed:issnTypePrintlld:pubmed
pubmed-article:3818496pubmed:volume18lld:pubmed
pubmed-article:3818496pubmed:ownerNLMlld:pubmed
pubmed-article:3818496pubmed:authorsCompleteYlld:pubmed
pubmed-article:3818496pubmed:pagination709-13lld:pubmed
pubmed-article:3818496pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3818496pubmed:meshHeadingpubmed-meshheading:3818496-...lld:pubmed
pubmed-article:3818496pubmed:meshHeadingpubmed-meshheading:3818496-...lld:pubmed
pubmed-article:3818496pubmed:meshHeadingpubmed-meshheading:3818496-...lld:pubmed
pubmed-article:3818496pubmed:meshHeadingpubmed-meshheading:3818496-...lld:pubmed
pubmed-article:3818496pubmed:meshHeadingpubmed-meshheading:3818496-...lld:pubmed
pubmed-article:3818496pubmed:meshHeadingpubmed-meshheading:3818496-...lld:pubmed
pubmed-article:3818496pubmed:meshHeadingpubmed-meshheading:3818496-...lld:pubmed
pubmed-article:3818496pubmed:meshHeadingpubmed-meshheading:3818496-...lld:pubmed
pubmed-article:3818496pubmed:meshHeadingpubmed-meshheading:3818496-...lld:pubmed
pubmed-article:3818496pubmed:meshHeadingpubmed-meshheading:3818496-...lld:pubmed
pubmed-article:3818496pubmed:year1986lld:pubmed
pubmed-article:3818496pubmed:articleTitlePharmacokinetics of mezlocillin in patients with hepatobiliary dysfunction.lld:pubmed
pubmed-article:3818496pubmed:publicationTypeJournal Articlelld:pubmed